What this means
This trial plans to build and test a new brain scan method at 7 Tesla strength. It has not started recruiting, and no results have been posted yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 18–130
- Where
- 1 site
The science
- Registered title
- Monitoring of Brain Metabolites Using Proton and Deuterium MR Techniques
- Trial ID
- NCT06705010 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Aging, Brain Metabolic Disorder, Carotid Stenosis, Alzheimer Disease, Diabetes Type 2, Mild Cognitive Impairment, Brain Disease
- What is tested
- Application of new pulse sequence package SIGNATURES2023 to healthy controls, Application of new pulse sequence package SIGNATURES2023 to 4 groups of patients (pilot)
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Ages
- 18 Years to 130 Years
- Dates
- First posted Nov 26, 2024 · updated Mar 25, 2025
Registry summary
MR pulse for whole brain optimal Deuterium (2H) Metabolic Imaging and EPSI (echo planar spectroscopic imaging) based SLOW-edited 1H-MRSI will be developed and optimized for use at an UHF scanner at 7 Tesla. The study has 4 phases.
Phase I: The 2H and 1H MRSI sequences are developed and optimized in vitro (phantoms)
Phase II: Sequences are applied in vivo in healthy volunteers and further optimized
Phase III: Optimal 2H 1H pulse sequences are applied in 4 cohorts of healthy volunteers, to study the effect of aging with whole brain 2H and 1H MRSI.
Phase IV: application of the sequences in 4 patient groups with different diseases: Alzheimer's diseases (AD) patients, diabetes mellitus type II (DM) patients, mild cognitive impaired (MCI) patients, and high grade carotid stenosis patients (HGCS).
The ultimate aim is to create for individual patient specific 3dimensional spatial resolved z-score maps (similar to FDG-PET) based on the healthy control data of phase III of the trial.
Sites (1)
- Translational Imaging Center / Sitem, Bern, Switzerland